“By 2050 Parkinson’s disease will have become a greater public health challenge for patients, their families, care givers, communities and society,” the study says. While modeling projected ...
Clinical Trials Arena on MSN6d
Cerevance to proceed with Phase III Parkinson’s trial despite Phase II setbackThe pivotal, Phase III study will evaluate the change in average daily “OFF” time in solengepras patients compared to placebo ...
Until the tremors started. The diagnosis of Young Onset Parkinson’s Disease was a surprise to the London resident. “You know ...
The primary outcome was the change from baseline to postintervention in mean Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) III scores. Also assessed during the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback